1990 Annual Report

1990-91 CHAIRMAN
John P. Munson
Svntex Pharmaceuticals
International Ltd.

LVTERNA TIOXAL SECTION
The International Section concentrated on the movement toward a unified European market
by 1992 and the Uruguay Round of trade negotiations on the General Agreement on Tariffs and Trade
(GATT). The Section also worked on actions by several governments-most notably the United Kingdom,
West Germany and Japan-to modify their drug programs. The Section continued to press for stronger
intellectual-property protection, with most success in the European Community, Latin America and Eastern
Europe.
The Section worked on achieving a consensus on a product-approval system for the European
Community that would avoid creating a drug lag in Europe, and on ensuring that reimbursement programs do not adversely affect the industry's ability to finance research and development. The Section
also sought to obtain effective intellectual property protection in the newly emerging free economies of
Eastern Europe.
The Section addresses such matters as international organizations; national
and international regulatory issues; market-access problems; investment restrictions;
non-tariff barriers; local-production requirements; licensing; price controls; and international patent and trademark issues. Top international executives, lawyers, intellectualproperty rights experts and public affairs officers are members of the Section.
PAL STAFF LL4AISON P1A BOARD LIALSO.S
Harvey E. Bale, Jr., Ph.D. John E. Lyons
Senior Vice President William R. Miller
Eugene L. Step
LA W SECTION
The Law Section worked on prescription-drug coverage and reimbursement issues under
Medicaid, both at the federal and state level. The Section also presented comments to the FDA on the
agency's proposed rule to implement Title I of the Drug Price Competition and Patent Term Restoration
Act of 1984, which deals with the assertion of patent rights, marketing exclusivity and bioequivalence.
In addition, the Section, through its Trademark and Copyright Committee, commented to the U.S. Patent
and Trademark Office on regulations to implement the Trademark Law Revision Act
of 1988, which established an intent-to-use trademark registration system in the U.S.
The principal role of the Law Section is to provide legal guidance to the Board
of Directors on legislative and regulatory issues that affect the industry. Company attorneys with a wide range of expertise in corporate and regulatory law are active in
the Section.
PMJA STAFF LIAISON PMA BOARD LLAIS105
Bruce J. Brennan Philip R. Tracy
Senior Vice President and
General Counsel

1990-91 CHAIRMAN
Santo J. Costa, Esq.
Glaxo Inc

22